Phase 2 N=13 Intranasal Oxytocin in Hypothalamic Obesity
Craniopharyngioma · Hypothalamic Obesity
Primary: Weight Loss — 88.3; 91.9; 1.2; 0.9 kg — p=0.92
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Open-Label Study of Setmelanotide in Hypothalamic Obesity
Hypothalamic Obesity
Primary: Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment — 88.9 percentage of participants — p=<0.0001
Phase 2 N=19 Effects of Exenatide on Hypothalamic Obesity
Hypothalamic Obesity
Primary: BMI Change — -0.77 kg/m^2 — p=.05
N/A N=112 A Cohort Study of Weight Loss and Gliosis
Obesity, Gliosis, Weight-Loss
Primary: Percent Change in Weight From Baseline — -6.1; -21.2; 1.2 percentage change from baseline — p=<0.001
N/A N=3 Deep Brain Stimulation Effects on Weight Change and Metabolic Rate
Obesity
Primary: Change in Metabolic Rate — 7.6; 18 percentage of increase in REM and SEE
Phase 3 N=42 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Hypothalamic Obesity
Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Phase 2 N=23 The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Obesity · Sarcopenic Obesity · Sarcopenia
Primary: Change in Body Weight — 0.54; 0.04 Kilograms
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
N/A N=31 Gastrointestinal Hormonal Regulation of Obesity
Obesity
Primary: Change in Body Weight From Baseline to 12 Months — 1.09; 1.55 lbs
N/A N=30 Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
N/A N=24 Growth Hormone as a Determinant of Weight Regulation
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Phase 2 N=22 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
Hypothalamic Injury-induced Obesity (HIO)
Primary: Number of Participants With Treatment Emergent Adverse Events — 12; 7 Participants
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=62 Reproductive Hormonal Alterations in Obesity
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
N/A N=6 Effects of Intermittent Hypoxia (IH) on Metabolism and Dysglycemia, in Overweight/Obese Persons SCI
Spinal Cord Injuries · Obesity · Insulin Resistance
Primary: Change in Cardioendocrine Risk by Surrogate Blood Measures of the Homeostasis Model Assessment - Insulin Resistance (HOMA 2-IR) — 1.67; 1.60 IR Score
N/A N=92 Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals
Feeding Behavior · Obesity · Overweight
Primary: Change in Food Image Ratings — -5.1; -.3; -6.8; -2.7 Score change from baseline — p=0.038
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
Phase 2 N=63 Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Traumatic Brain Injury
Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor
N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
N/A N=20 Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
Obesity
Primary: Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) — .0468; .0492…
N/A N=16 The Role of Altered Nutrient Partitioning in Food Reward
Overweight and Obesity
Primary: Change in Preference- Liking — 6.5; 4.5 units on a scale
N/A N=26 Effect of Increased Free Fatty Acids on Leptin Function
Obesity · Leptin Resistance
Primary: Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels — 7147; 11725; 11898; 28060 pM*min
Phase 4 N=23 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
Hypogonadism · Severe Obesity
Primary: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion — 12.6; 8.9; 12.8; 3.7 Percent change in muscle strength
Phase 2 N=31 Trial of Leptin Administration After Roux-en-Y Gastric Bypass
Overweight
Primary: Weight Change (in kg.) After Each Intervention — -0.39; 0.02 kg weight change
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL